- Home
- CGEN vs BANX Comparison
CGEN vs BANX Comparison
Compare CGEN & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- BANX
- Stock Information
- Founded
- CGEN 1993
- BANX 2013
- Country
- CGEN Israel
- BANX United States
- Employees
- CGEN N/A
- BANX N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- BANX Trusts Except Educational Religious and Charitable
- Sector
- CGEN Health Care
- BANX Finance
- Exchange
- CGEN Nasdaq
- BANX Nasdaq
- Market Cap
- CGEN 135.6M
- BANX 149.0M
- IPO Year
- CGEN 2000
- BANX N/A
- Fundamental
- Price
- CGEN $1.47
- BANX $20.24
- Analyst Decision
- CGEN Strong Buy
- BANX
- Analyst Count
- CGEN 1
- BANX 0
- Target Price
- CGEN $4.00
- BANX N/A
- AVG Volume (30 Days)
- CGEN 268.4K
- BANX 25.8K
- Earning Date
- CGEN 05-19-2025
- BANX 06-13-2025
- Dividend Yield
- CGEN N/A
- BANX 10.45%
- EPS Growth
- CGEN N/A
- BANX N/A
- EPS
- CGEN N/A
- BANX 2.35
- Revenue
- CGEN $27,864,000.00
- BANX $29,467,794.00
- Revenue This Year
- CGEN $11.81
- BANX N/A
- Revenue Next Year
- CGEN $28.37
- BANX N/A
- P/E Ratio
- CGEN N/A
- BANX $8.61
- Revenue Growth
- CGEN N/A
- BANX 2.73
- 52 Week Low
- CGEN $1.13
- BANX $17.91
- 52 Week High
- CGEN $2.66
- BANX $21.67
- Technical
- Relative Strength Index (RSI)
- CGEN 49.50
- BANX 51.50
- Support Level
- CGEN $1.13
- BANX $18.37
- Resistance Level
- CGEN $1.35
- BANX $19.24
- Average True Range (ATR)
- CGEN 0.11
- BANX 0.67
- MACD
- CGEN 0.03
- BANX 0.06
- Stochastic Oscillator
- CGEN 85.00
- BANX 71.66
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds, and others.